The protein kinase C␤ (PKC␤) gene encodes two isoforms, PKC␤I and PKC␤II, as a result of alternative splicing. The unique mechanism that underlies insulininduced alternative splicing of PKC␤ pre-mRNA was examined in L6 myotubes. Mature PKC␤II mRNA and protein rapidly increased >3-fold following acute insulin treatment, while PKC␤I mRNA and protein levels remained unchanged. Mature PKC␤II mRNA resulted from inclusion of the PKC␤II-specific exon rather than from selection of an alternative polyadenylation site. Increased PKC␤II expression was also not likely accounted for by transcriptional activation of the gene or increased stabilization of the PKC␤II mRNA, and suggest that PKC␤II expression is regulated primarily at the level of alternative splicing. Insulin effects on exon inclusion were observed as early as 15 min after insulin treatment; by 20 min, a new 5-splice site variant of PKC␤II was also observed. After 30 min, the longer 5-splice site variant became the predominate species through activation of a downstream 5 splice site. Similar results were obtained using IGF-I. Although the role of this new PKC␤II mRNA species is presently unknown, inclusion of either PKC␤II-specific exon results in the same PKC␤II protein.
Protein kinase C␤ (PKC␤)
1 is a member of the PKC family, which is a serine/threonine kinase family that mediates cellular responses elicited by hormones, neurotransmitters, and growth factors (1) (2) (3) . The PKC␤ gene encodes two mRNAs that originate from alternative splicing of exons encoding the carboxyl terminus (see Fig. 1A ) (4) . The resulting polypeptides, PKC␤I and PKC␤II, diverge in the sequence of their COOHterminal 50 (PKC␤I) or 52 (PKC␤II) amino acids, respectively (4, 5) . PKC␤ is involved in insulin-stimulated glucose transport based on studies in the BC3H-1 myocytes, rat soleus muscle, adipocytes, L6 myotubes, and vascular smooth muscle cells (6 -11) . Our work demonstrated that PKC␤I and -␤II have different and distinct functions in response to insulin in stable transfectants of NIH-3T3 fibroblasts (12) . PKC␤II overexpression enhanced insulin-stimulated 2-deoxyglucose uptake significantly above control cells or stable transfectants overexpressing PKC␤I (12) . The contribution of PKC␤II activity to insulin-stimulated [ 3 H]2-deoxyglucose uptake was also examined in rat L6 myotubes, a cell line phenotypically similar to skeletal muscle expressing GLUT4 and GLUT1 type glucose transporters (8) . Transient expression of a PKC␤II-specific dominant negative blocked insulin-stimulated 2-deoxyglucose uptake (8) . CG53353, a PKC␤II-specific inhibitor at 1 M, also inhibited insulin-stimulated 2-deoxyglucose uptake (8) . Thus, one alternative splice variant of the PKC␤ gene is more effective than the other as a positive transducer for glucose transport responses.
The regulation of PKC␤ gene expression has not been extensively studied. Our laboratory was the first to demonstrate that expression of these two messages was regulated acutely by insulin (12) . In BC3H-1 myocytes, insulin induced alternative splicing of the PKC␤ mRNA, thereby switching expression from PKC␤I to PKC␤II mRNA (12) . The switch in mRNA was reflected by increased protein levels of PKC␤II (12) . However, the mechanism of how insulin regulated the post-transcriptional processing of PKC␤ pre-mRNA was unclear. There were several options. For example, insulin could affect polyadenylation site selection to define the carboxyl terminus, and, in another case, insulin could affect the inclusion of the PKC␤II-specific exon into the mature message since the PKC␤II-specific exon includes a translation stop codon. Increased transcription or changes in PKC␤II mRNA stability may also affect post-transcriptional processing. In this report, each of these possibilities were considered in L6 skeletal muscle cells, which, unlike the BC3H-1 myocytes, express the GLUT4 type glucose transporter and are a fully differentiating cell model for insulin action. We demonstrate that insulin specifically enhances the inclusion of an exon encoding the last 52 COOH-terminal amino acids of PKC␤II. Insulin also activated two 5Ј splice sites, a previously known site and a second newly identified 5Ј splice site, to include the PKC␤II-specific exon, which contains a stop codon, thereby encoding only the PKC␤II protein. This is the first report of a hormone affecting the 5Ј splice site selection in pre-mRNA. Since our knowledge of alternative splicing is derived primarily from in vitro biochemical approaches, this study expands our understanding of how splicing is regulated in vivo in eukaryotes and demonstrates L6 skeletal muscle cells as a model for hormone-induced alternative splicing.
MATERIALS AND METHODS
Cell Culture-L6 rat skeletal myoblasts (obtained from Dr. Amira Klip, The Hospital for Sick Children, Toronto, Canada) were grown in ␣-minimum essential medium (␣-MEM) supplemented with 10% fetal bovine serum (Sigma) to confluence. Myoblasts were fused into myotubes by changing media to ␣-MEM supplemented with 2% fetal bovine serum for 2-4 days after confluence. Cells were incubated in ␣-MEM ϩ 0.1% bovine serum albumin for 6 h and placed in phosphate-buffered saline (PBS) ϩ 0.1% bovine serum albumin just prior to treatment with insulin (200 nM) or IGF-I (Long R 3 IGF-I, GroPep) (20 ng/ml). For mRNA stability studies, actinomycin D (10 g/ml) was added 5 min prior to addition of insulin or PBS sham control.
Reverse Transcriptase-Polymerase Chain Reaction-Total RNA was isolated from L6 myotubes (13) and 1 g was used to synthesize first strand cDNA using an oligo(dT) primer and Superscript II reverse transcriptase (Life Technologies pre-amplification kit). For quantitative RT-PCR, 5% of the cDNA was amplified in the presence of 10 Ϫ2 amol of mimic DNA using primers specific for PKC␤I, PKC␤II, or ␤-actin and Taq DNA polymerase from Perkin-Elmer. The PKC␤II-specific primers correspond to Primer A, a sense primer to the V3 region of PKC␤ (5Ј-ATGAAACTGACCGATTTTAACTTCCTG-3Ј), and Primer B, an antisense primer corresponding to the V5 region of PKC␤II (5Ј-CGGAG-GTCTACAGATCTACTTAGCTCT-3Ј) (Fig. 1B) . The PKC␤I-specific primers were Primer C, a sense primer corresponding to the C3 region (5Ј-CCGCCTCTACTTTGTGATGGA-3Ј), and Primer D, an antisense primer corresponding to the V5 region of PKC␤I (5Ј-TGCCTGGT-GAACTCTTTGTCG-3Ј) (Fig. 1B) . Sense and antisense primers for ␤-actin (CLONTECH) were used to normalize for total RNA. Mimics (competitors) for PKC␤I and PKC␤II were constructed using the CLONTECH MIMIC construction kit (CLONTECH). The mimic is a neutral piece of DNA containing primer sequences for either PKC␤I or PKC␤II on its 5Ј and 3Ј ends. The mimic will specifically compete for primer binding sites with the target PKC␤I or PKC␤II cDNA. Extension rates of competitor mimics are within 5% of the target cDNA extension rate. Following 30 cycles of amplification in a Biometra Trioblock thermocycler (␤-actin and PKC␤II: 94°C, 1 min; 58°C, 1 min; and 72°C, 3 min; PKC␤I: 94°C, 30 s; 58°C, 30 s; and 72°C, 1 min), 20% of the PCR reaction was resolved on a 1% agarose gel. The photograph of the ethidium bromide-stained PCR products was quantified by scanning densitometry.
For evaluating PKC␤II-specific exon inclusion, Primer E, an upstream sense primer corresponding to the C4 kinase domain common to both PKC␤I and -␤II (5Ј-GTTGTGGGCCTGAAGGGGAACG-3Ј), and Primer D (described above) were used. This RT-PCR assay allows for relative comparison of PKC␤II versus PKC␤I mRNA levels.
For evaluating PKC␤II 5Ј splice site selection, Primer F, a sense primer corresponding to the PKC␤II exon (5Ј-CACCCGCCATCCAC-CAGTCCT-3Ј) and Primer D (described above) were used. This method allows for comparing different PKC␤II alternative splice products.
To examine potential expression of the polyadenylated form of PKC␤II, Primer E (described above) and Primer G, an antisense primer corresponding to intronic sequences upstream from the PKC␤II polyadenylation signal and downstream of the PKC␤II exon (5Ј-CGGGAAG-GTGGAAGAATGTTGC-3Ј), were used.
Following 35 cycles of a two-step PCR amplification program (95°C, 30 s; and 68°C, 2 min) using Taq-Gold DNA polymerase from PerkinElmer, 15% of the PCR reactions were resolved by electrophoresis on 1.5% agarose gels. The gel was then denatured 30 min in a 0.5 M NaOH, 1 M NaCl solution, neutralized 30 min in a 1 M Tris-HCl, 1 M NaCl solution, and blotted via capillary transfer to nylon membranes. Membranes were hybridized with a 32 P-labeled PKC␤ cDNA probe as described below.
For insulin receptor isoform analysis, primers specific for the exons flanking the alternatively spliced exon 11 of the insulin receptor were used to amplify reverse transcribed total RNA. The sequences are (5Ј-GTCCCCACCTTTTGAGTCTGA-3Ј) for the sense primer to exon 10 and (5Ј-AAATGGTCTGTGCTCTTCGTG-3Ј) for the antisense primer to exon 12. Following 35 cycles of a three-step PCR amplification program (95°C, 30 s; 64°C, 30 s; and 72°C, 2 min), PCR reactions were resolved and quantitated as described above.
Western Blotting-L6 myotube cell lysates (40 g) were subjected to 9% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (14) . Proteins were electrophoretically transferred to nitrocellulose membranes, blocked with Tris-buffered saline, 0.1% Tween 20 containing 5% nonfat dried milk, washed, and incubated with a polyclonal antibody against either the COOH terminus of PKC␤II or PKC␤I (Santa Cruz Technologies and Dr. Yoshiko Akita, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan). Detection was performed using enhanced chemiluminescence (ECL, Amersham).
Random Prime Labeling-PKC␤II cDNA (25 ng) was labeled with [␣-32 P]CTP (3000 Ci/mmol) using random prime labeling (14) . Labeled cDNA was purified from unincorporated nucleotides using G50 Sephadex chromatography (14) .
Southern Blot Analysis-DNA was transferred to Hybond N nylon membrane (Amersham) and baked at 80°C for 2 h. Blots were prehybridized for 1 h in 5 ϫ SSC, 5 ϫ Denhardt's solution, 0.5% sodium dodecyl sulfate (SDS), and 50% formamide at 43°C. Random prime labeled PKC␤II cDNA (1 ϫ 10 6 cpm) was added, and blots were hybridized for 16 h at 43°C and washed for 15 min at room temperature with 1 ϫ SSC, 0.1% SDS and 0.1 ϫ SSC, 0.1% SDS. Blots were exposed to an imaging screen and quantitated using the Molecular Dynamics PhosphorImager system.
Transient Transfections and Reporter Gene Assays-PKC␤ promotor (Ϫ2200 to ϩ43) constructs were cloned into a luciferase reporter plasmid as described previously (15) . L6 rat skeletal muscle myotubes were grown in 35-mm tissue culture dishes and co-transfected with 3.5 g of the PKC␤ promotor/luciferase construct and 1 g of SV40 ␤-galactosidase vector using the calcium phosphate method (14) . Cells were incubated in calcium phosphate/DNA precipitate for 16 h, washed twice with phosphate-buffered saline, and placed in medium (2% fetal bovine serum) for 8 h (14) . Serum was removed for 6 h prior to insulin (200 nM) treatment. Cells were lysed with 1 ϫ lysis buffer (Promega Corp.) and assayed for luciferase and ␤-galactosidase activity following the manufacturer's protocol (Promega Corp.).
Sequencing-All PCR products were verified by sequencing at the University of South Florida Genome Center.
RESULTS

Insulin Increased PKC␤II Mature mRNA and Had No Effect
on PKC␤I Mature mRNA Levels-Although insulin regulation of alternative splicing of PKC␤II pre-mRNA has been reported previously in BC3H-1 myocytes, the mechanism by which insulin affected splicing was not examined. Since the mechanism is likely to be relevant in insulin action, we used L6 myotubes in this study. These cells represent a model of fully differentiated skeletal muscle myotubes that express GLUT4 type glucose transporters, in contrast to the BC3H-1 myocytes. Using competitive RT-PCR, the expression of PKC␤II mature mRNA was examined in response to acute insulin treatment in differentiated L6 myotubes (Fig. 1B) . Upon treatment with insulin (200 nM) for 15 min, a 3-fold increase in PKC␤II mRNA was observed (Fig. 2) . The up-regulation of PKC␤II mRNA increased 3.5-4-fold at 1 h after insulin treatment. This extended our earlier findings in BC3H-1 myocytes to L6 myotubes for examining the molecular basis of hormone-induced alternative splicing.
To quantify potential changes in PKC␤I mRNA levels via competitive RT-PCR, cycling conditions were optimized to efficiently amplify the 684-bp PKC␤I PCR product and not other species. Unlike the BC3H-1 myocytes, no change occurred in PKC␤I mRNA with acute insulin treatment (Fig. 2 ). This may reflect the difference between an undifferentiated cell line such as the the BC3H-1 myocytes and a differentiated cell type like the L6 myotubes. This may also suggest that there is a functional role for PKC␤I in insulin signal transduction in the L6 myotubes. PKC␤I and -␤II mRNA levels were normalized to ␤-actin mRNA levels using competitive RT-PCR (data not shown).
The PKC␤II mRNA Increase Is Reflected at the Protein Level-To examine whether insulin effects on PKC␤I and -␤II mRNA were reflected at the protein level, polyclonal antibodies specific for the COOH terminus of either PKC␤I or PKC␤II proteins were used for detection on Western blots. Insulin treatment increased PKC␤II immunoreactive protein levels greater than 3.5-fold (350%), while PKC␤I immunoreactive protein levels remained unchanged (Fig. 3) . The data shown are composites of five separate experiments with each time point examined for an individual effect. Thus, the increase in PKC␤II mRNA expression was directly reflected at the protein level between 15 min and 24 h as with the BC3H-1 myocytes. Differences in the amount of basal PKC␤II immunoreactive protein between experiments are attributed to variables in cell culture and sensitivity of chemiluminescence detection. The overall increase in PKC␤II immunoreactive protein following insulin treatment was consistent.
The Rapid Up-regulation in PKC␤II mRNA Was Not Reflected by Increased Transcriptional Activity-If the alternative splicing that leads to mature PKC␤II mRNA is under negative regulation by a limited amount of RNA transactivating factors, a rapid increase in PKC␤ pre-mRNA via transcriptional activation may account for increased PKC␤II expression. To examine whether the up-regulation of PKC␤II mRNA was related to an increase in transcriptional activity, several PKC␤ promotor constructs of varying lengths including a (Ϫ2200 to ϩ43) construct were examined for insulin responsiveness. The PKC␤ promotor (Ϫ511 to ϩ43)/luciferase construct was the only construct activated in response to insulin following transient transfection (data not shown). This construct contains an AP2, an E-box, and two Sp1 sites. With this construct, no change in PKC␤ promotor/luciferase activity was observed within 30 min and only modest increases were noted after 16 h. Based on these data and the observation that PKC␤I mRNA is not increased in response to insulin, the early increase in PKC␤II mRNA was not likely due to an increase in transcriptional activity of the PKC␤ gene. Treatment with tetradecanoyl phorbol acetate to activate the promotor and transfection with a fully active SV40/luciferase construct were used as positive controls to demonstrate promotor activation (15) . Transfection efficiency was normalized using a ratio of the co-transfected pSV-␤-galactosidase activity.
The Early Up-regulation in PKC␤II mRNA Was Not Likely Due to Increased Message Stability-The possibility of posttranscriptional regulation of PKC␤II expression at the level of message stability was also evaluated. To demonstrate whether PKC␤II mRNA was up-regulated via increases in message stability, insulin effects on PKC␤I and PKC␤II mRNA levels were determined after treatment with the transcription inhibitor, actinomycin D, after 1 h of acute insulin treatment. Using competitive RT-PCR, no differences in mRNA levels were detected between control and insulin-treated L6 myotubes (data not shown). This suggests that insulin effects on PKC␤II message were not likely due to rapid increases in mRNA stabilization. Also of note is the observation that insulin did not destabilize PKC␤I message as in the BC3H-1 myocytes, demonstrating either the lack of a hormone-induced destabilization system or a requirement for PKC␤I in insulin-activated metabolic or mitogenic processes in L6 myotubes.
Alternative Polyadenylation Site Selection Did Not Occur in Response to Insulin-Since insulin treatment did not result in transcriptional activation or increased message stability, the possibility that PKC␤II expression was regulated primarily at the level of alternative splicing was likely. Early studies by Nishizuka and co-workers (4) suggested PKC␤II mRNA is encoded via inclusion of the PKC␤II exon into the mature mRNA transcript in brain tissue. In B lymphoblastoid cells, however, Hannun and co-workers (16) demonstrated that polyadenylation site selection might govern PKC␤II splicing. Based on the information available about the arrangement of terminal exons in the PKC␤ gene, it was possible that the alternatively spliced PKC␤II mRNA resulted from one of these two mechanisms, inclusion of the PKC␤II-specific exon or alternative polyadenyl-
Competitive RT-PCR analysis of PKC␤I and -␤II mRNA levels in L6 myotubes after insulin treatment. L6 myotubes were removed from serum for 6 h prior to treatment with either 200 nM insulin or PBS (sham control) for various times. Total RNA was extracted, reverse transcribed, and subjected to competitive PCR using synthetic competitors for PKC␤I or PKC␤II primer binding sites (see Fig. 1B) . Target designates the reverse transcribed mature mRNA, and mimic designates synthetic competitor DNA. The PKC␤II target length was 1030 bp, and the mimic length was 748 bp using primers A and B. The PKC␤I target length was 684 bp, and the mimic length was 398 bp using primers C and D. PCR products were resolved by fractionation on 1.2% agarose gels and visualized via ethidium bromide staining. PCR products were verified by sequencing. Shown is a representative analysis that was repeated on five separate occasions with different L6 myotube preparations. ation site selection, in L6 myotubes. Regulation of either mechanism by a hormone had not been demonstrated. In the case of polyadenylation site selection, insulin would activate a polyadenylation site located downstream of the PKC␤II exon, thereby producing mature PKC␤II mRNA. In the case of an exon inclusion mechanism, the PKC␤I polyadenylation site would be used, but a stop codon in the PKC␤II exon terminates translation and results in a protein with the PKC␤II COOH terminus. If the PKC␤II exon were skipped, then PKC␤I would be encoded. To determine if the increase in PKC␤II mRNA was due to regulation of PKC␤II polyadenylation site selection, an RT-PCR-based assay was designed. Using primer E, a sense primer to the C4 region, and primer G, an antisense primer to a sequence downstream of the PKC␤II exon and near the PKC␤II polyadenylation site, only a polyadenylated form of PKC␤II mRNA could be amplified. Neither control L6 myotubes nor insulin-treated L6 myotubes expressed a polyadenylated form of PKC␤II even after 55 PCR cycles (Fig. 4) . Therefore, the increase in PKC␤II mRNA in response to insulin was not likely due to regulation of PKC␤II polyadenylation site selection. As a positive control, 10 Ϫ3 amol of a PKC␤II cDNA containing the 3Ј-untranslated region of the polyadenylated form of PKC␤II was amplified (obtained from Dr. S. Ohno, Yokohama City University School of Medicine, Yokohama, Japan).
Insulin Enhanced the Inclusion of the PKC␤II Exon into the Mature mRNA Transcript-Since alternative polyadenylation site selection did not likely account for the effect of insulin on PKC␤II expression, the possibility that insulin affected inclusion of the PKC␤II-specific exon in L6 myotubes was a likely alternative. An RT-PCR assay that allowed for the simultaneous detection of PKC␤II and PKC␤I mRNA utilizing primer E, a sense primer to the upstream PKC␤ common exon (C4 kinase domain), and primer D, an antisense downstream primer specific for PKC␤I (V5 domain) was designed (Fig. 5, A and B) . In response to acute insulin treatment, PKC␤II message (374-bp PCR product) increased to levels that exceeded PKC␤I message (153-bp PCR product) (Fig. 6) . The amount of mature PKC␤II mRNA increased from 15% exon-included message to 60% by 15 min to a maximum of 80% exon-included message at 30 min after treatment with insulin. This demonstrated that insulin rapidly enhanced inclusion of the PKC␤II-specific exon.
Identification of a Previously Unidentified 5Ј Splice Site for the PKC␤II Exon Encoding an Additional Splice Variant of
PKC␤II-An additional, longer PCR product was also observed following exon inclusion analysis, which did not correspond to the anticipated PKC␤II amplification product (Figs. 6) (4) . The new fragment hybridized with a labeled PKC␤ cDNA probe upon Southern blot analysis suggesting that the amplified fragment was not artifactual. Sequence analysis revealed it was a new splice variant of PKC␤II, which included approximately 136 nucleotides of additional extended 3Ј-untranslated sequence (Fig. 5C ). After comparing this sequence to the published sequence of the PKC␤II exon and surrounding intronic sequences, the activation of a second 5Ј splice site, CAG/GTG-GCAT, was demonstrated (Fig. 7A) (4) . Insulin action culminated in the activation of both 5Ј splice sites that resulted in exon inclusion (Fig. 7, A and B) .
Insulin Sequentially Activates a Second 5Ј Splice Site in the PKC␤II Exon-To further investigate the effects of insulin on exon inclusion and the activation of the two 5Ј splice sites, we amplified the region between the PKC␤II exon and the PKC␤I terminal exon (Fig. 5, A and C) . This RT-PCR-based assay examines specifically exon-included PKC␤II mRNA and there- FIG. 4 . The PKC␤II mature mRNA encoded using the PKC␤II polyadenylation site is not expressed in L6 myotubes. RT-PCR analysis of L6 myotubes treated with PBS (sham control) or insulin (200 nM) for 15 min using primer E, a primer to the C4 region common to both PKC␤I and -␤II, and primer G, a primer specific for the downstream PKC␤II intronic sequence between the polyadenylation site and the nearest 5Ј splice site (see "Materials and Methods" for primer sequences). Prior to assay, the cells were removed from serum for 6 h. fore increases our detection sensitivity for PKC␤II message. We found that insulin activated the second downstream 5Ј splice site in a time-dependent manner. After a 20 min insulin treatment, activation of the second splice site was detected by RT-PCR followed by Southern blot analysis. By 30 min after insulin treatment, the second splice site was preferentially activated since the longer transcript "exceeded" transcripts using the conventional 5Ј splice site by a ratio of 2 to 1 (Fig. 8) . Acute IGF-I treatment also activated the second 5Ј splice site at 30 min, demonstrating that other related peptide hormones have the capability of affecting PKC␤II exon inclusion and 5Ј splice site selection in L6 myotubes (Fig. 8) . This is the first report of a hormone affecting 5Ј splice site selection and the first report of IGF-I affecting alternative splicing.
Insulin Effects on mRNA Splicing Are Specific for PKC␤II mRNA in L6 Myotubes-The effect of insulin on alternative splicing of the insulin receptor was also reported in FAO cells, but the mechanism was neither specified nor elucidated. To examine if the effects of insulin on exon inclusion reflect a more general effect on splicing, the potential regulation of insulin receptor exon 11 inclusion was examined in L6 myotubes. Primers that amplified from exon 10 to exon 12 of the insulin receptor gene were used to observe the inclusion of the insulin receptor exon 11 (17) . In control and insulin-treated L6 myotubes, both type A (exon 11 excluded) and type B (exon 11 included) insulin receptor mRNA were detected with type B receptor mRNA predominating (85%). As shown in Fig. 9 , insulin, however, had no affect on the ratio of type A to type B insulin receptor mRNA after 30 min. These results suggest that insulin's effects on exon inclusion are probably not a general phenomenon, but specifically targeted to certain pre-mRNAs. DISCUSSION Our earlier studies in the BC3H-1 myocytes demonstrated that PKC␤II expression was regulated by insulin (12) . L6 myotubes were used to determine the mechanism responsible for insulin effects on PKC␤II expression. The BC3H-1 myocytes used in previous studies were a non-fusing cell line and only expressed GLUT1 transporters. A fully differentiated cell line such as the L6 cell line that more closely resembles skeletal muscle expressing both GLUT4 and GLUT1 type glucose transporters provides a more physiologically relevant model for studying splicing (18) . To examine PKC␤I and PKC␤II mRNA levels, a highly sensitive method to quantitate mRNA levels by RT-PCR was developed. In L6 myotubes, as in the BC3H-1 myocytes, mature PKC␤II mRNA and protein increased more than 3.5-fold following acute insulin treatment. Levels of PKC␤I mature mRNA and immunoreactive protein remained unchanged following insulin treatment. Prior studies in the BC3H-1 myocytes showed that PKC␤I mRNA and protein levels decreased in response to insulin. This was due to destabilization of PKC␤I mRNA in response to insulin. The different observations between the two cell types may be explained in two ways. The lack of a insulin-induced destabilization system in the L6 myotubes or a role for PKC␤I in insulin action in the L6 myotubes. Other findings from our laboratory suggest a role for PKC␤I in insulin action. We found that overexpression of PKC␤I in L6 myotubes overcomes the inhibition of insulinstimulated 2-deoxyglucose uptake by wortmannin, a phosphatidylinositol 3-kinase inhibitor (19) . Overexpression of PKC␤I in L6 myotubes also increases insulin-stimulated glycogen synthase activation. 2 These data suggest that PKC␤I as FIG. 7 . A, revised PKC␤ 3Ј gene structure. Schematic diagram depicts the 3Ј end of the PKC␤ gene with approximate sizes of exons and introns from sequence analysis (4). Polyadenylation sites are designated AATAAA for PKC␤II and ATTAAA for PKC␤I. Enlarged schematic of the PKC␤II exon depicts 5Ј splice site sequences along with RNA cis-elements. Black dots represent short (10 -14 bp) purine-rich exon splicing enhancers, ESE designates a large 38-bp purine-rich exon splicing enhancer, Stem loop structure reflects a 44-bp AUUUA stem loop structure, PYR designates a 30-bp pyrimidine-rich tract, and SRp40 depicts a binding site for phosphorylated SRp40. B, structure of PKC␤I and -␤II splice variants. Schematic represents the 3Ј end of PKC␤I and PKC␤II mature mRNA. I) reflects PKC␤I mature mRNA; II) reflects PKC␤II mature mRNA derived from exon inclusion and deduced from rat brain; III) reflects a splice variant for PKC␤II with extended 5Ј-untranslated region derived from L6 myotubes; IV) reflects PKC␤II mRNA derived from alternative polyadenylation selection. ␤C, the nearest exon shared by both PKC␤I and -␤II. well as PKC␤II have distinct roles in the metabolic effects of insulin. However, the mechanism by which insulin affected PKC␤ pre-mRNA splicing had not been elucidated, and whether PKC␤ pre-mRNA preferentially processed to PKC␤I or PKC␤II mature mRNA was not known. It also remained to be elucidated whether PKC␤ pre-mRNA splicing was positively or negatively regulated by insulin and whether RNA transactivating factors were involved. Transactivating factors are known to be involved in regulating post-transcriptional as well as transcriptional events (20) .
A possible mechanism to preferentially increase PKC␤II mRNA expression could be through increased transcriptional activation in response to insulin. In this case, the RNA splicing of PKC␤ pre-mRNA to mature PKC␤II mRNA may be negatively regulated in the basal state. For example, in the absence of insulin RNA transactivating factors may inhibit the inclusion of the PKC␤II-specific exon or recognition of the PKC␤II polyadenylation site, thereby leading to the production of mature PKC␤I mRNA. A rapid increase in the transcription of the PKC␤ gene in response to insulin may increase the levels of PKC␤ pre-mRNA. If the inhibitory RNA transactivating factors are limiting, the newly transcribed PKC␤ pre-mRNA would be processed to mature PKC␤II mRNA. The PKC␤ message occurs at relatively low levels. Therefore, to investigate the possibility of a transcriptional mechanism of regulation, we initially evaluated the effect of insulin on several PKC␤ promotor/luciferase constructs spanning Ϫ2200 to ϩ43 bp (15) . Only a Ϫ511/ϩ43 PKC␤ promotor construct was activated by insulin. All other constructs, including a Ϫ2200 to ϩ43 bp construct, exhibited no response to insulin. Insulin stimulation of the Ϫ511/ϩ43 bp PKC␤ promotor construct occurred, however, at later times (16 h), and induction was minimal. Hence, the increase in PKC␤II mRNA was not likely accounted for at the level of transcriptional activation, although one could argue that the promotor constructs used required an upstream enhancer element to respond to insulin.
An increase in PKC␤II mRNA stability could also increase PKC␤II mRNA levels in response to insulin. To determine if increases in PKC␤II mRNA were due to increased mRNA stability, relative decay rates of PKC␤I and PKC␤II mRNA were measured following actinomycin D treatment. Relative decay rates did not change within 1 h of insulin treatment, and the increase in PKC␤II mRNA levels were not likely justified by increased PKC␤II mRNA stability.
Mature PKC␤II mRNA could also result from alternative exon selection or alternative polyadenylation site selection (4, 12, 16) . The regulation of either nuclear mechanism by an external cell receptor signaling cascade had not been reported. In the L6 myotubes, we found that PKC␤II mRNA was produced via inclusion of an exon that encodes a stop codon defining the V5 region of PKC␤II in response to insulin treatment. This mechanism produces a message with the PKC␤I exon including a polyadenylation site spliced onto the 3Ј end of the PKC␤II exon (Fig. 7B) . Insulin regulation of PKC␤II exon inclusion changed the ratio of PKC␤I to PKC␤II mRNA following insulin treatment. The levels of newly processed PKC␤II mRNA exceeded the synthesis of PKC␤I mRNA, demonstrating that insulin enhanced PKC␤II exon inclusion into the mature mRNA transcript.
The molecular mechanism through which insulin affects PKC␤II exon inclusion has not been addressed. Our findings suggest that alterations in splicing factors associated with the PKC␤II exon may be occurring. Several RNA cis-elements that are known to affect exon inclusion and splice site selection were presently identified in the PKC␤II exon and its surrounding intronic sequences. They include a binding site for phosphorylated SRp40, several purine-rich exon splicing enhancers, and multiple pyrimidine tracts (Fig. 7A) . 2 Serine/arginine-rich (SR) proteins and pyrimidine tract-binding protein are known RNA transactivating factors that bind to these cis-elements and affect exon inclusion and 5Ј splice selection (21) . Since SR proteins can be regulated via phosphorylation by SR protein kinases (22, 23) , it is possible that insulin may activate a protein kinase that modulates SR protein phosphorylation and their RNA binding properties thereby affecting exon inclusion.
An even more novel mechanism of insulin regulation of PKC␤ pre-mRNA splicing was the observation that insulin activated a second 5Ј splice site downstream of the previously reported 5Ј splice site for the PKC␤II exon. This additional downstream 5Ј splice site was preferentially activated compared with the conventional 5Ј splice site by 30 min after insulin treatment. This second splice variant for PKC␤II extended the 3Ј-untranslated region by approximately 136 nucleotides. The observation that insulin activated two 5Ј splice sites for PKC␤II exon inclusion is intriguing. The time-dependent manner in which the downstream 5Ј splice site is activated following insulin treatment suggests that the additional untranslated region serves a functional purpose. This novel mechanism may introduce features into the newly spliced PKC␤II mRNA that further regulate translation, long term stability, or nuclear export of mature mRNA. Extending this observation, we found that IGF-I also stimulated splicing via exon inclusion and activated the second 5Ј splice site. This is the first report of IGF-I affecting the alternative splicing of pre-mRNA and suggests that both peptides stimulate similar signaling pathways culminating in nuclear post-transcriptional processing of mRNA.
Insulin effects on exon inclusion appear to have some specificity, since it did not further alter the inclusion of exon 11 into insulin receptor mRNA, another gene whose pre-mRNA splicing has been demonstrated to be affected rapidly by insulin (17) . This, therefore, argues against widespread activation of RNA trans-activating factors and nonspecific insulin effects on splicing. These data also suggest a different insulin signaling pathway or RNA processing mechanism for regulation of PKC␤ pre-mRNA splicing compared with insulin receptor mRNA splicing.
PKC␤ is activated and translocated by insulin in L6 myotubes, and we have previously reported that PKC␤II is associated with enhanced insulin-stimulated 2-deoxyglucose uptake, thus suggesting a physiological significance for increasing PKC␤II expression (8, 12, 24) . A possible link of PKC␤II to insulin-stimulated 2-deoxyglucose uptake could be hypothesized by the fact that PKC␤II specifically encodes an F-actin binding site in its V5 region that PKC␤I does not encode. PKC␤II specifically binds and is activated by F-actin (25) . The actin cytoskeleton undergoes rapid rearrangement in response to acute insulin treatment in a phosphatidylinositol 3-kinasedependent manner (26) . Disassembly of the actin network with cytochalasin D inhibits insulin-stimulated GLUT4 translocation in L6 muscle cells (27) . Therefore, PKC␤II may function in the process of insulin-stimulated actin rearrangement leading to activation or translocation of glucose transporters to the plasma membrane in L6 myotubes.
In conclusion, PKC␤II expression is increased through enhanced exon inclusion and additional 5Ј splice site activation, which introduces a new COOH-terminal exon containing a stop codon that defines the V5 region of PKC␤II. This is the first report of insulin altering nuclear mRNA processing through 5Ј splice site regulation. Insulin regulation of post-transcriptional splicing events demonstrates a novel mechanism for hormonal responses to rapidly alter gene expression.
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